Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9U5LY
|
|||
| Drug Name |
REGN3051
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Coronavirus infection [ICD-11: 1D92; ICD-10: B34.2] | Phase 1 | [1] | |
| Company |
Regeneron Pharmaceuticals; Sanofi
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | COVID-19 spike glycoprotein (S) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03301090) A Safety, Tolerability, Pharmacokinetics and Immunogenicity Trial of Co-administered MERS-CoV Antibodies REGN3048 and REGN3051. U.S. National Institutes of Health. | |||
| REF 2 | Prophylactic and therapeutic efficacy of mAb treatment against MERS-CoV in common marmosets. Antiviral Res. 2018 Aug;156:64-71. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.